DiaMedica Therapeutics Inc. (DMAC)
| Market Cap | 430.87M +17.9% |
| Revenue (ttm) | n/a |
| Net Income | -37.54M |
| EPS | -0.72 |
| Shares Out | 53.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,231 |
| Open | 8.01 |
| Previous Close | 8.13 |
| Day's Range | 7.95 - 8.42 |
| 52-Week Range | 5.25 - 10.42 |
| Beta | 0.91 |
| Analysts | Strong Buy |
| Price Target | 15.50 (+93.99%) |
| Est. Earnings | Nov 11, 2026 |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 93.99% from the latest price.
News
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw major clinical progress for DM199 in FGR, preeclampsia, and stroke, with key trial enrollments and regulatory steps advancing. Cash reserves of $43.5M support operations through 2027 as R&D spending rises with program expansion.
DiaMedica Therapeutics Quarterly report: Q2 2026
DiaMedica Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
DiaMedica Therapeutics Earnings release: Q2 2026
DiaMedica Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c)
“With the recent positive interim results from Part 1a of our Phase 2 study evaluating DM199 in preeclampsia, we’re eager to continue advancement of this promising candidate to address ischemic…
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics announces dosing of first two patients in DM199 study
DiaMedica Therapeutics (DMAC) announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 for the treatment of fetal growth restriction. This is the firs...
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute is...
DiaMedica Therapeutics receives written response from FDA on DM199
DiaMedica Therapeutics (DMAC) announced that it has received a written response from the U.S. Food and Drug Administration, FDA, regarding the need for additional nonclinical reproductive toxicity dat...
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Dru...
DiaMedica Therapeutics Slides: Corporate presentation
DiaMedica Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial
DiaMedica Therapeutics (DMAC) announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199in patients with acute ischemic stroke, AIS, has reached 75% of the 200-patient threshold require...
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and ...
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Earnings Call Transcript: Q1 2026
DM199 clinical programs in preeclampsia and stroke advanced, with key milestones and interim analyses expected by end of 2026. Cash reserves of $51.3M support operations through 2027, while R&D expenses rose 40% year-over-year.
DiaMedica Therapeutics Earnings release: Q1 2026
DiaMedica Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
DiaMedica Therapeutics Quarterly report: Q1 2026
DiaMedica Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c)
“We continue to focus on moving our clinical programs forward. Looking ahead, we anticipate four separate preeclampsia data readouts and a readout from our fetal growth restriction trial between now…
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restrict...
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...
DiaMedica Therapeutics Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
A synthetic KLK1 protein therapy is advancing in trials for preeclampsia and stroke, showing strong safety and efficacy signals, with multiple clinical readouts expected through next year. The company is well-funded, targeting large unmet needs, and leverages extensive Asian clinical data.